Key Takeaways
- Trade generics drove the quarter: Revenue grew 8.1% YoY, powered by a 73.2% YoY surge in trade generics, while CDMO stayed flat against a tough base and industry-wide volume decline.
- Margins inched up despite investment: EBITDA margin expanded to 11.5% from 11.2% YoY; the lift from higher-margin trade generics was partly offset by accelerated R&D and product development spend.
- CDMO flat is not CDMO broken: Management insists the flat quarter is cyclical (COVID base effect, industry destocking), not structural, and points to new launches and the Sitagliptin patent expiry as near-term growth triggers.
- The balance sheet is ready for inorganic moves: Nearly ₹200 crores in reserves and strong cash flow give the company room to evaluate acquisitions, though nothing is finalized.
- What to watch next quarter: Whether Sitagliptin commercialization lifts CDMO growth, the pace of trade generics stockist additions, and any update on the injectable facility timeline.
CDMO: Flat Quarter, Unchanged Story
- The base effect was real: Q1 FY22 CDMO revenue was inflated by COVID-driven demand for Vitamin C, Ivermectin, combination kits and sanitizers; those products are now gone, replaced by new launches and other contracts.
- Industry headwinds compounded it: The broader Indian pharma market saw 8–9% volume degrowth in Q1 as customers adjusted inventories and waited for input prices to fall; supply chain issues slowed conversion of new opportunities.
- Vildagliptin did not move the needle: Many large cardiovascular players launched it from in-house, so the expected CDMO opportunity did not materialize at scale.
- The growth playbook is three-pronged: Take the existing product portfolio to new clients, add new products and offer them to both old and new clients, and bring differentiated capabilities in capacity, product development, quality and innovation.
- Sitagliptin is the near-term catalyst: The patent expired on 6th July; Windlas commercialized it on day zero for several clients, and the impact is expected to show in Q2.
- Contracts are sticky, not guaranteed: Typical CDMO contracts run five years, with some multinational agreements having no termination date; average relationships exceed seven years, and the company does not recall losing any customer over its history. But these are master services agreements, not take-or-pay contracts.
Hitesh Windlass: "My sense is that strategically and structurally, there is no change. We expect the CDMO vertical also on the back of our new product launches and patent expiries like you mentioned, to come back into growth phase."
Trade Generics: The Growth Engine
- 73% growth on a small base: Trade generics revenue jumped 73.2% YoY, lifting its share of total revenue to 18% from the 10–12% range; rapid stockist and distributor additions drove the traction.
- The umbrella brand is working: Branding activities for "Windlas generic" in the sales channel are paying off, with engagement showing signs of very strong traction.
- The structural opportunity is vast: India has only about 400 towns with over one lakh population, but six and a half lakh villages and kasbas below that threshold; in these places, the branded generic model does not work because there are few doctors and patients must travel for medicines.
- Revenue contribution target is 15–20%: Management expects trade generics to stay in that range over three to four years, even as the other verticals grow; the current growth rate is far beyond the tripling target in the five-year plan, but it comes off a smaller base.
- Government tenders are a slow-burn opportunity: Jan Aushadhi and Ayushman Bharat tenders are expected to increase gradually; the company sees them as viable, long-term opportunities and is actively pursuing them.
Hitesh Windlass: "Our idea and philosophy is that we will give authentic, affordable and accessible products in this trade generics vertical is what we are leading with."
Margins: Mix Help, R&D Drag
- Trade generics lifted gross margins: The vertical carries higher material margins than CDMO, so its outsized growth improved overall material margins on a YoY basis.
- R&D spend held back the flow-through: EBITDA margin expanded only 30 bps to 11.5% because accelerated R&D costs and product development/registration expenses absorbed some of the gross margin gain.
- R&D is overwhelmingly product-focused: 85–90% of R&D spend goes to new product development, concentrated on chronic therapies where fixed-dose combinations are the treatment of choice due to drug resistance or physician preferences.
- Long-term R&D target is ~2% of revenue: That is roughly double the FY20–21 level of about 1% or slightly above; the acceleration is deliberate and expected to impact margins in the short run while building the top line over the long term.
- CDMO margin stability held despite input spikes: Metformin prices rose 3–4x and Paracetamol saw huge changes, but CDMO margins were protected because the business runs on a cost-plus model.
- Future CDMO margin expansion hinges on operating leverage: Fixed costs do not change much with higher volumes, so better capacity utilization is the primary lever; gross margin is the more representative metric to track over time.
Hitesh Windlass: "In a B2B environment, if you get desperate to fill capacity, you very quickly lose margin. And so, our focus has been to not go after the largest opportunities, not go after the smallest and sort of target this medium space, where we are doing something complex, and we are able to offer a sustainable partnership to our customer."
Regulatory & Facility Updates
- EU GMP certification secured: Plant-IV received the certification, and the company is now looking at non-US regulated as well as some semi-regulated markets.
- US FDA remediation complete: The company has submitted its final response and is ready for re-inspection, but the FDA provides no visibility or schedule; management reiterated there is no plan to build a business in the US or commercialize ANDAs there.
- SAHPRA filings in progress: A couple of products have been filed for registration in South Africa with Cipla as the commercial partner; dossier approval is expected, but timing depends on the agency's review.
- Injectable facility shifted to domestic machinery: Geopolitical uncertainty around delivery times for imported machinery prompted a switch to domestic manufacturers; the change was made to bring definiteness to the timeline.
- First commercial batch targeted by March FY23: The timeline depends on media fill and validation completion; an update is expected in the current quarter, and the company still aims to hit the original target date.
- CAPEX should stay within plan: Expenditure is expected to come very close to the proposed value in FY23, with no cost escalation anticipated.
Strategic Direction
- Complex generics are the moat: The company is increasing concentration on 75% complex generics, believing that is the sustainable space where customers need them and they add differentiated value; simple products can be taken in-house or shifted to competitors.
- The five-year plan is explicit: Double CDMO, triple trade generics, quadruple exports, all from their respective bases.
- Exports are tiny but targeted for growth: The base is very small and Q1 was stagnant due to client buying cycles, but full-year growth is still expected; the company is also evaluating CDMO opportunities for export markets, though cycle times are longer due to dossier updates and tech transfers.
- Inorganic growth is on the radar: Management is evaluating several ideas and has nearly ₹200 crores in reserves plus strong cash flow to deploy, but nothing is finalized and no timing can be committed.
- Customer breadth is expanding: Over 75 customers were added in the quarter, though sales from them will materialize over time; more than 200 customers were served, with some having no sales in the period.
Komal Gupta: "We don't recall losing any customer over the period of the life of the customer."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| CDMO revenue doubling | Double CDMO business from FY22 base | Over five years (by FY27) |
| Trade generics revenue share | 15% to 20% of overall revenue | Three to four years |
| Trade generics scale | Triple the business from its base | Over five years (by FY27) |
| Exports scale | Quadruple the business from its base | Over five years (by FY27) |
| Injectable facility first commercial batch | First batch out | By March FY23 (end of FY23) |
| R&D spend target | Around 2% of revenue | Long-term, no specific year |
| CDMO growth resumption | Growth to return on back of new launches and Sitagliptin patent expiry | Q2 FY23 onward |
Key Metrics
| Metric | Q1 FY23 |
|---|---|
| Consolidated revenue | ₹119.9 crores, up 8.1% YoY |
| Consolidated EBITDA | ₹13.8 crores, up 11.4% YoY |
| Consolidated PAT | ₹9.8 crores, up 46.6% YoY |
| EBITDA margin | 11.5%, up from 11.2% YoY; expansion limited by accelerated R&D costs |
| CDMO vertical revenue | ₹94.8 crores, largely flattish YoY; contributed ~79% of consolidated revenue |
| Trade generics vertical revenue | ₹21.4 crores, up 73.2% YoY; contributed ~18% of consolidated revenue |
| Trade generics margin premium | 4% to 5% higher than CDMO business margin |
| CDMO long-term growth target | Double CDMO business over five years |
| Trade generics long-term growth target | Triple trade generics business over five years |
| Exports long-term growth target | Quadruple exports business over five years |
| Complex generics share of output | 75% of output this quarter |
| Capacity utilization | ~40% |
| New CDMO customers added in Q1 | more than 75 new customers added; sales to ramp over time |
| R&D spend target | ~2% of revenue long-term, up from ~1% in FY20-21 |
| Cash reserves on balance sheet | ~₹200 crores |